Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats
查看参考文献37篇
|
文摘
|
Aim: To investigate the effects of the selective serotonin reuptake inhibitor (SSRI) fluoxetine on extracellular matrix (ECM) remodeling of the pulmonary artery and inflammation of the lungs in pulmonary arterial hypertension (PAH) induced by monocrotaline in rats. Methods: MCT-induced chronic PAH was established in Wistar rats. After treatment with fluoxetine for 3 weeks, pulmonary hemodynamic measurement and morphological investigation of lung tissues were undertaken. The main components of the ECM, elastin and collagen, were detected using Van Gieson stain and Orcein stain, respectively, or using Victoria-ponceau's double stain. The ECM proteolytic enzymes matrix metalloproteinase (MMP)-2 and MMP-9, and the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2, were detected by Western blot. Inflammation of lung tissue was assayed using lung morphology and inflammatory cytokine expression. Results: Fluoxetine (2 and 10 mg/kg) significantly inhibited MCT-induced PAH, attenuated pulmonary arterial muscularization and ECM remodeling, and decreased MMP/TIMP expression. Fluoxetine also suppressed inflammatory responses in lung tissue and inhibited the expression of the inflammatory cytokines interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-β), monocyte chemotactic protein (MCP-1) and intercellular adhesion molecule-1 (ICAM-1). Conclusion: Fluoxetine inhibited MCT-induced ECM remodeling of the pulmonary artery and inflammation of lung tissue. These effects were related to its inhibition on MMPs/TIMPs and cytokine productions |
|
来源
|
Acta Pharmacologica Sinica
,2011,32(2):217-222 【核心库】
|
|
DOI
|
10.1038/aps.2010.187
|
|
关键词
|
extracellular matrix
;
inflammation
;
pulmonary arterial hypertension
;
selective serotonin reuptake inhibitor
|
|
地址
|
Department of Clinical Pharmacology, College of Pharmacy, China Medical University
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1671-4083 |
|
学科
|
药学 |
|
基金
|
国家自然科学基金
|
|
文献收藏号
|
CSCD:4124334
|
参考文献 共
37
共2页
|
|
1.
Morrell NW. Cellular and molecular basis of pulmonary arterial hypertension.
J Am Coll Cardiol,2009,54:S20-S31
|
被引
54
次
|
|
|
|
|
2.
Tuder RM. Pathology of pulmonary arterial hypertension.
Semin Respir Crit Care Med,2009,30:376-385
|
被引
5
次
|
|
|
|
|
3.
Raiesdana A. Pulmonary arterial hypertension.
Ann Med,2006,38:95-110
|
被引
2
次
|
|
|
|
|
4.
Eble JA. The extracellular matrix of blood vessels.
Curr Pharm Des,2009,15:1385-1400
|
被引
7
次
|
|
|
|
|
5.
Lammers SR. Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves.
Am J Physiol Heart Circ Physiol,2008,295:H1451-H1459
|
被引
1
次
|
|
|
|
|
6.
Frisdal E. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension.
Eur Respir J,2001,18:838-845
|
被引
5
次
|
|
|
|
|
7.
Ambalavanan N. Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions.
Pediatr Res,2008,63:26-32
|
被引
1
次
|
|
|
|
|
8.
Novotna J. Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia.
Physiol Res,2002,51:323-334
|
被引
2
次
|
|
|
|
|
9.
Lepetit H. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension.
Eur Respir J,2005,25:834-842
|
被引
10
次
|
|
|
|
|
10.
Aytekin M. High levels of hyaluronan in idiopathic pulmonary arterial hypertension.
Am J Physiol Lung Cell Mol Physiol,2008,295:L789-L799
|
被引
1
次
|
|
|
|
|
11.
MacLean MR. Serotonin and pulmonary hypertension -from bench to bedside.
Curr Opin Pharmacol,2009,9:281-286
|
被引
2
次
|
|
|
|
|
12.
MacLean MR. The serotonin hypothesis of pulmonary hypertension revisited.
Adv Exp Med Biol,2010,661:309-322
|
被引
8
次
|
|
|
|
|
13.
Kereveur A. High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (prostacyclin) therapy.
Arterioscler Thromb Vasc Biol,2000,20:2233-2239
|
被引
2
次
|
|
|
|
|
14.
Song D. 5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent.
Acta Pharmacol Sin,2005,26:563-567
|
被引
5
次
|
|
|
|
|
15.
Li XQ. Sertraline protects against monocrotaline-induced pulmonary hypertension in rats.
Clin Exp Pharmacol Physiol,2006,33:1047-1051
|
被引
4
次
|
|
|
|
|
16.
Zhai FG. Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kvl.5 channels in rats.
Clin Exp Pharmacol Physiol,2009,36:850-856
|
被引
4
次
|
|
|
|
|
17.
Dorfmuller P. Inflammation in pulmonary arterial hypertension.
Eur Respir J,2003,22:358-363
|
被引
19
次
|
|
|
|
|
18.
Mathew R. Inflammation and pulmonary hypertension.
Cardiol Rev,2010,18:67-72
|
被引
3
次
|
|
|
|
|
19.
Chaouat A. Role for interleukin-6 in COPD-related pulmonary hypertension.
Chest,2009,136:678-687
|
被引
19
次
|
|
|
|
|
20.
Hassoun PM. Inflammation, growth factors, and pulmonary vascular remodeling.
J Am Coll Cardiol,2009,54:S10-S19
|
被引
19
次
|
|
|
|
|
了解气象卫星更多信息，请访问